FOXO4-DRI Protocol: There Is No Clinical Document

The word is doing different work in different places, and separating the uses resolves most of the confusion.

A clinical protocol specifies eligibility, dose, route, schedule, endpoints, safety monitoring and stopping rules. It is reviewed by an ethics committee and registered before anyone enrols. None exists for this compound.

An experimental protocol is the methods section of a laboratory study. Several exist and are public, all in animals or cell culture.

A clinic protocol is a service package: a sequence of appointments, injections and follow-ups sold as a programme. It carries no regulatory status and is not derived from clinical evidence, because none exists to derive it from.

The 2017 study used several arms. Mice were given doxorubicin at 10 mg/kg to induce senescence, then FOXO4-DRI at 5 mg/kg on days 1, 3 and 5, intravenously. Separate arms used fast-ageing XpdTTD/TTD mice and naturally aged mice, dosed intraperitoneally, measuring fitness, fur density and renal function.

Later work applied the compound in its own systems: aged mouse Leydig cells, keloid fibroblasts, murine pulmonary fibrosis, and human chondrocytes in culture.

The dosing was intermittent for a mechanistic reason. A senolytic clears a cell population, and once cleared there is nothing further to act on until those cells re-accumulate, which takes months to years. Continued exposure adds risk without benefit.

Set aside safety for a moment and consider only whether following a protocol could tell you anything.

The endpoints used in the research are senescence-associated beta-galactosidase staining, p16 and p21 quantification, inflammatory secretory profiling, and in the 2017 work a p16-driven bioluminescent reporter imaged in living animals.

None of these is available outside a laboratory. There is no home-observable measure of senescent-cell clearance, which means a person following any protocol would have no way of determining whether anything had happened.

That is a stronger objection than it first appears. It means even a well-intentioned self-experiment generates no information.

Preclinical toxicology across species establishing a safety margin. Then a phase 1 trial whose purpose is tolerability, dose-ranging and pharmacokinetics rather than efficacy. Only after that does anyone have a defensible starting dose.

None of this has begun, and a programme attempting it would need to address a specific finding rather than merely proceed carefully. A 2023 study reported that clearing senescent cells could promote pulmonary hypertension development and progression.

Our affiliate disclosure sets out how we are paid.